Search research articles
Contact Us
Filters
Showing results (811-820 of 910) with videos related to
Page
of 91
Sort By:
Gene Therapy
|
March 27, 2025
Optimization of adeno-associated viral (AAV) gene therapies vectors for balancing efficacy, longevity and safety for clinical application
Neel Mehta, Rénald Gilbert, Parminder S Chahal, et al.
Journal of the American College of Cardiology
|
October 7, 2004
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease
G Kees Hovingh, Alison Brownlie, Radjesh J Bisoendial, et al.
Neurobiology of Disease
|
February 10, 2015
Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease
Amber L Southwell, Sonia Franciosi, Erika B Villanueva, et al.
Translational Neurodegeneration
|
October 8, 2024
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice
Nicholas S Caron, Lauren M Byrne, Fanny L Lemarié, et al.
Pediatric Blood & Cancer
|
February 27, 2013
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children
H Visscher, C J D Ross, S R Rassekh, et al.
Human Molecular Genetics
|
July 6, 2016
An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes
Amber L Southwell, Amy Smith-Dijak, Chris Kay, et al.
Cardiovascular Diabetology
|
August 1, 2018
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
Annayya R Aroor, Nitin A Das, Andrea J Carpenter, et al.
Cell Death & Disease
|
September 26, 2020
pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model
Xiaohong Xu, Bryan Ng, Bernice Sim, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
August 14, 2024
The frequency and clinical impact of synonymous HTT loss-of-interruption and duplication-of-interruption variants in a diverse HD cohort
Jessica Dawson, Chris Kay, Hailey Findlay Black, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
February 27, 2018
Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice
Raphael Chevre, Laia Trigueros-Motos, David Castaño, et al.
Page
of 91
Search research articles
Search
Showing results (811-820 of 910) with videos related to
Sort By:
Page
of 91
Gene Therapy
|
March 27, 2025
Optimization of adeno-associated viral (AAV) gene therapies vectors for balancing efficacy, longevity and safety for clinical application
Neel Mehta, Rénald Gilbert, Parminder S Chahal, et al.
Journal of the American College of Cardiology
|
October 7, 2004
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease
G Kees Hovingh, Alison Brownlie, Radjesh J Bisoendial, et al.
Neurobiology of Disease
|
February 10, 2015
Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease
Amber L Southwell, Sonia Franciosi, Erika B Villanueva, et al.
Translational Neurodegeneration
|
October 8, 2024
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice
Nicholas S Caron, Lauren M Byrne, Fanny L Lemarié, et al.
Pediatric Blood & Cancer
|
February 27, 2013
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children
H Visscher, C J D Ross, S R Rassekh, et al.
Human Molecular Genetics
|
July 6, 2016
An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes
Amber L Southwell, Amy Smith-Dijak, Chris Kay, et al.
Cardiovascular Diabetology
|
August 1, 2018
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
Annayya R Aroor, Nitin A Das, Andrea J Carpenter, et al.
Cell Death & Disease
|
September 26, 2020
pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model
Xiaohong Xu, Bryan Ng, Bernice Sim, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
August 14, 2024
The frequency and clinical impact of synonymous HTT loss-of-interruption and duplication-of-interruption variants in a diverse HD cohort
Jessica Dawson, Chris Kay, Hailey Findlay Black, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
February 27, 2018
Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice
Raphael Chevre, Laia Trigueros-Motos, David Castaño, et al.
Page
of 91